Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
88
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer

Zhenwei Wang1 Department of Urinary Surgery, Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China;2 Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, People’s Republic of ChinaView further author information
,
Zhihong Dai1 Department of Urinary Surgery, Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6995-9522View further author information
ORCID Icon,
Bingwei Wang2 Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, People’s Republic of ChinaView further author information
,
Yuren Gao1 Department of Urinary Surgery, Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaView further author information
,
Xiang Gao1 Department of Urinary Surgery, Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaView further author information
,
Liang Wang1 Department of Urinary Surgery, Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaView further author information
,
Sihai Zhou1 Department of Urinary Surgery, Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaView further author information
,
Liqin Yang1 Department of Urinary Surgery, Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaView further author information
,
Xiaofu Qiu2 Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, People’s Republic of China;3 The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, People’s Republic of ChinaView further author information
&
Zhiyu Liu1 Department of Urinary Surgery, Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 4383-4389 | Published online: 04 Aug 2021

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
  • Rini BI, Small EJ. Hormone-refractory prostate cancer. Curr Treat Options Oncol. 2002;3(5):437–446. doi:10.1007/s11864-002-0008-1
  • Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. doi:10.1056/NEJMoa041318
  • Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–250. doi:10.1200/JCO.2014.56.2728
  • Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):6981–6996. doi:10.1056/NEJMoa1506859
  • Marshall CH, Fu W, Wang H, et al. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis. 2019;22(1):59–65.
  • Criscuolo D, Morra F, Giannella R, et al. Identification of novel biomarkers of homologous recombination defect in DNA repair to predict sensitivity of prostate cancer cells to PARP-inhibitors. Int J Mol Sci. 2019;20(12):12. doi:10.3390/ijms20123100
  • Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev. 2008;18(1):87–96. doi:10.1016/j.gde.2008.02.001
  • Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res. 2004;91:31–67.
  • Medova M, Aebersold DM, Zimmer Y. MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. Int J Cancer. 2012;130(3):728–734. doi:10.1002/ijc.26058
  • Du Y, Yamaguchi H, Wei Y, et al. Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016;22(2):194–201. doi:10.1038/nm.4032
  • Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(5):429–440. doi:10.1016/j.ccr.2009.03.020
  • Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi:10.1158/0008-5472.CAN-09-1947
  • Speit G, Rothfuss A. The comet assay: a sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol. 2012;920:79–90.
  • Muranen T, Selfors LM, Worster DT, et al. Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix- Attached Cancer Cells. Cancer Cell. 2012;21:227–239
  • Gildemeister OS, Sage JM, Knight KL. Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C. J Biol Chem. 2009;284(46):31945–31952. doi:10.1074/jbc.M109.024646
  • Bottaro DP, Rubin J, Faletto D, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802–804. doi:10.1126/science.1846706
  • Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 1995;147(2):386–396.
  • Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002;60(6):1113–1117. doi:10.1016/S0090-4295(02)01954-4
  • Chu YY, Yam C, Chen MK, et al. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res. 2020;10(2):648–661.
  • Sahin ID, Jonsson J-M, Hedenfalk I. Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer. Oncotarget. 2019;10(65):6981–6996. doi:10.18632/oncotarget.27363
  • Bonilla B, Hengel SR, Grundy MK, et al. RAD51 gene family structure and function. Annu Rev Genet. 2020;54(1):25–46. doi:10.1146/annurev-genet-021920-092410
  • Sung P, Robberson DL. DNA strand exchange mediated by a RAD51-ssDNA nucleoprotein filament with polarity opposite to that of RecA. Cell. 1995;82(3):453–461. doi:10.1016/0092-8674(95)90434-4
  • Sak A, Stueben G, Groneberg M, et al. Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br J Cancer. 2005;92(6):1089–1097. doi:10.1038/sj.bjc.6602457

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.